Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different

BACKGROUND: Tuberculosis (TB), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: LaHood, Allison, Rahman, Rifat, McKenna, Lindsay, Frick, Mike, Mitnick, Carole D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312388/
https://www.ncbi.nlm.nih.gov/pubmed/35877601
http://dx.doi.org/10.1371/journal.pone.0271102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312388/
https://www.ncbi.nlm.nih.gov/pubmed/35877601
http://dx.doi.org/10.1371/journal.pone.0271102

Ejemplares similares